Novel therapeutic for the treatment of ocular pathologies
LSU Health Sciences Center - New Orleans, Louisiana, United States
This technology is a treatment for corneal tissue pathology following viral infection, medical procedures, and accidental injury. Demonstrated by extensive testing in an in vivo rabbit eye system, the therapeutic has a strong anti-viral effect, is a potent anti-inflammatory agent, and has an anti-angiogenic effect while simultaneously promoting corneal healing.
Primary Application Area: Pharmaceuticals & Personal Care
Technology Development Status: Prototype
Technology Readiness Level: TRL 3
FIGURES OF MERIT
Value Proposition: Distinct advantages of this new therapeutic include reduced risk of secondary infections, a more rapid healing response, and no vision loss due to corneal clouding.
Organization Type: Academic/Gov Lab
Showcase Booth #: 737
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date: NIH P20RR021970
Primary Sources of Funding: Federal Grant, University
Looking for: Development / License Partners